Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ray Sison
11.23.22 -- CDMO Selection In Our Post-COVID World
By Ray Sison In a post-pandemic world, we need to explore a broader view of our new reality. This article shares some of the concepts currently playing out in biopharmaceutical outsourcing that will impact your CDMO selection strategy. Additional discussion touches on how new outsourcing players will fit in and the path forward.
11.11.22 -- Are Immunotherapeutic Vaccines The Next Biologic Revolution?
By Matthew Pillar, Editor, BioProcess Online Vaxxinity, small as it may be on the greater pharma landscape, is carving out positions as innovator, disruptor, and leader in what CEO Mei Mei Hu, J.D. refers to as the third biologic revolution. Here, she shares Vaxxinity's position on immunotherapeutic vaccines in the context of traditional vaccines and biologics and offers insight into the company's unique culture.
11.08.22 -- CDMO Selection In Our Post-COVID World
By Ray Sison In a post-pandemic world, we need to explore a broader view of our new reality. This article shares some of the concepts currently playing out in bio/pharmaceutical outsourcing that will impact your CDMO selection strategy. Additional discussion touches on how new outsourcing players will fit in and the path forward.
11.02.22 -- Stand Shoulder-To-Shoulder With Your CDMO
By Ray Sison, xCell Strategic Consulting In a post-pandemic world, we need to explore a broader view of our new reality. This article shares some of the concepts currently playing out in biopharmaceutical outsourcing that will impact your CDMO selection strategy. Additional discussion touches on how new outsourcing players will fit in and the path going forward.
CDMO Selection In Our Post-COVID World
Get more biosimilar development insight with our FREE newsletter sign me up Home Development Manufacturing Regulatory Editorial Board Guest Column | October 28, 2022 By Ray Sison It’s official; according to the president of the United States, the pandemic is over. This means that trade shows are now in-person, with virtual attendance as an option, and CDMOs have finally returned to allowing in-person site visits after being forced to prohibit non-essential workers from entry for nearly two years.
CDMO Selection In Our Post-COVID World Original
Get more pharma outsourcing insight with our FREE newsletter sign me up Development Contract Manufacturing Packaging Logistics Market Research Guest Column | October 28, 2022 By Ray Sison It’s official; according to the president of the United States, the pandemic is over.
CDMO Selection In Our Post-COVID World
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Guest Column | October 28, 2022 By Ray Sison It’s official; according to the president of the United States, the pandemic is over. This means that trade shows are now in-person, with virtual attendance as an option, and CDMOs have finally returned to allowing in-person site visits after being forced to prohibit non-essential workers from entry for nearly two years.
01.07.21 -- Facility Engineering, Design, And Construction Tips For Up-Start Biotech Companies
By Herman F. Bozenhardt and Erich H. Bozenhardt Fledgling biotech companies are financially fragile, and they can ultimately become controlled by demanding fund managers. Those who manage facility engineering, design, and construction for these companies must adjust their thinking and employ some new tactics to document all costs and impacts, reduce schedules, and maintain quality. By Ray Sison On-site capability assessments are an indispensable part of the CDMO selection process.
CDMO Selection: Can We Eliminate The Onsite Audit?
By Ray Sison General consensus within the outsourcing community is that conducting on-site audits is a critical activity in CDMO selection. In June 2019 I wrote about the nuts and bolts of performing on-site capabilities audits in my article "How to Ace Your Next CDMO Capabilities Audit." In that article I strongly advocated for preparing for and making the effort to get out to meet top candidates in person, and readers agreed.
One-Stop Shop Or Best of Breed? 3 CDMO Selection Case Studies
By Ray Sison, VP of Pharmaceutical Outsourcing and Tech Transfer, xCell Strategic Consulting, LLC When outsourcing drug product development or back-end supply chain (SC), maintaining control of the process is essential. One way to establish control is by defining objectives and developing a stepwise plan to achieve them.
One-Stop Shop Or Best of Breed? 3 CDMO Selection Case Studies
By Ray Sison, VP of Pharmaceutical Outsourcing and Tech Transfer, xCell Strategic Consulting, LLC When outsourcing drug product development or back-end supply chain (SC), maintaining control of the process is essential. One way to establish control is by defining objectives and developing a stepwise plan to achieve them.
06.09.20 -- 2 Things Every Emerging Biopharma Needs To Know About Supply Chain
Newsletter | June 9, 2020 By Ray Sison, xCell Strategic Consulting, LLC For clinicians on the front lines with potential effective therapies who are exploring how to develop new drug products, as well as development-stage companies looking to manage clinical supply chains and transform their organization for product launch, a basic framework is needed in order to integrate supply chain operation into a business strategy.
06.04.20 -- Knowledge Management -- Opportunities & Challenges For Legacy Drug Products
By Prakash Patel, Sigmapharm Laboratories, and Igor Gorsky, ValSource, Inc. This article will explore specific challenges of managing knowledge in a legacy manufacturing environment and propose viable, practical solutions that have been found to be effective. These solutions allow practitioners to increase product and process understanding as well as performance.
2 Things Every Emerging Biopharma Needs To Know About Supply Chain
By Ray Sison, xCell Strategic Consulting, LLC There is an inside joke in drug product development: We enter our careers with visions of discovery and world-changing accomplishment. Then, one day we wake up in supply chain. With the world's sudden focus on supply chain, notably for healthcare and the drug development industry, supply chain professionals may yet have their moment.
2 Things Every Emerging Biopharma Needs To Know About Supply Chain
By Ray Sison, xCell Strategic Consulting, LLC There is an inside joke in drug product development: We enter our careers with visions of discovery and world-changing accomplishment. Then, one day we wake up in supply chain. With the world's sudden focus on supply chain, notably for healthcare and the drug development industry, supply chain professionals may yet have their moment.
2 Things Every Emerging Biopharma Needs To Know About Supply Chain
By Ray Sison, xCell Strategic Consulting, LLC There is an inside joke in drug product development: We enter our careers with visions of discovery and world-changing accomplishment. Then, one day we wake up in supply chain. With the world's sudden focus on supply chain, notably for healthcare and the drug development industry, supply chain professionals may yet have their moment.
Negotiating Quality Technical Agreements Strategies for Non-Quality Professionals
By Ray Sison, xCell Strategic Consulting, LLC In the CDMO selection process there are four critical documents that must be negotiated and executed by both the sponsor and CDMO. In order of execution, these documents are: Confidentiality Non-Disclosure Agreement Quotation Master Services Agreement (MSA) or Supply Agreement (SA) Quality Technical Agreement (QTA) Of these documents, the QTA is often the least prioritized by the procurement team.
CDMO Selection 3 Questions To Save Time And Reduce Stress When Reviewing An MSA
By Ray Sison, xCell Strategic Consulting, LLC Whether because of unfamiliarity or lack of resources, master service or supply agreement (MSA) execution can be time consuming and difficult. At any given pharma company in the development or clinical stage, the leadership team and investors prioritize patients, therapies, and trial results. Equally important to success is a drug product supply chain for manufacturing, packaging, and distribution.
During A Tech Transfer There Is No Substitute For Boots On The Ground
During A Tech Transfer, There Is No Substitute For Boots On The Ground By Ray Sison, VP of pharmaceutical outsourcing and tech transfer, xCell Strategic Consulting Here’s a situation that may sound familiar to process engineers: A campaign of three registration batches is scheduled to start next week at a new CMO so far away that getting there requires crossing borders (but only if management approves travel).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ray
Contact Ray, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack